Compare Equinor ASA (EQNR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Vertex Pharmaceuticals Incorporated — how do they compare? Equinor ASA trades at $41.14 (market cap $95.91B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Equinor ASA pays a 3.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EQNR | VRTX | |
|---|---|---|
Market Cap | $95.91B | $132.79B |
Sector | Energy | Health |
52-Week High | $42.40 | $529.65 |
52-Week Low | $22.41 | $376.62 |
Enterprise Value | $104.60B | $126.92B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $38.92, down 1.37% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.32% ROE and attractive valuation metrics, including a P/E of 10.55 and EV/EBITDA of 2.19. Recent Q2 2026 earnings missed estimates, but revenue grew 40% year-over-year, supported by higher energy prices and production. The company continues shareholder returns via dividends and a share buy-back program.
EQNR presents a mixed outlook: robust cash flow and strategic investments in subsea projects support growth, but declining net income margins and geopolitical energy market volatility pose risks. Analyst consensus is cautious with 30.43% buy ratings, reflecting fair valuation concerns after recent gains. The stock offers value through dividends and buybacks, yet investors face exposure to oil price swings and execution risks in capital projects.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
